The role of vehicles in dermatological treatment Review article
Article Sidebar
Main Article Content
Abstract
Topical treatment plays an important role in the dermatology. Its main advantage is direct access to the skin lesions and slight systemic influence connected with narrow spectrum of adverse events. Treatment impact of topical formulations depends not only on active substance, but also to a large extent on base that is used. Taking into consideration specific properties of the vehicle one should choose its adequate type depending on the character and localization of the skin lesions, the severity of the inflammation process and the clinical effect that we would like to achieve. Type of the vehicle has an influence on the absorption rate and the strength of the active substance. It also plays a crucial role in the acceptance of this form of therapy by the patient and the compliance in the course of treatment. New forms of the medicaments which combine features of different types of mediums make market debuts. Nowadays, creating vehicles that would provide high effectiveness of the therapy with an acceptable cosmetic properties, is a great challenge. The final effect of the therapy depends mainly on the patient compliance.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. Griffiths C., Barker J., Bleiker T. et al.: Rook’s Textbook of Dermatology. Wiley Blackwell 2016; 1: 18.1-18.8.
3. Weller R., Hunter J., Savin J. et al.: Clinical Dermatology. Blackwell Publishing 2009: 364-370.
4. Singh Malik D., Mital N., Kaur G.: Topical drug delivery systems: a patent review. Exp. Opin. Ther. Pat. 2016; 26(2): 213-228.
5. Gabard B., Elsner P., Surber C., Treffel P.: Dermatopharmacology of topical preparations. Springer, New York 2000: 5-21.
6. Weiss S.C.: Conventional topical delivery systems. Dermatol. Ther. 2011; 24: 471-476.
7. Reich K., Newley A.: What is new in topical therapy for psoriasis? J. Eur. Acad. Dermatol. Venereol. 2011; 25: 15-20.
8. Surber C., Smith E.W.: The mystical effects of dermatological vehicles. Dermatology 2005; 210: 157-168.
9. Wohlrab J.: Topical preparations and their use in dermatology. J. Dtsch Dermatol. Ges. 2016; 1061-1070.
10. Rosen J., Landriscina A., Friedman A.: Principles and approaches for optimizing therapy with unique topical vehicles. J. Drug. Dermatol. 2014; 13: 1431-1435.
11. Jaworek A.K., Wojas-Pelc A.: Znaczenie miejscowych glikokortykosteroidów we współczesnym lecznictwie dermatologicznym. Cz. 1. Farmacja Współczesna 2017; 10: 91-99.
12. Berg M., Svensson A., Faergemann J.: A novel formulation of mometasone furoate in psoriasis patients: a multicenter, randomized, double-blind clinical Study. Adv. Ther. 2013; 30: 503-516.
13. Carroll C.L., Feldman S.R., Camacho F.T., Balkrishnan R.: Better medication adherence results in greater improvement in severity of psoriasis. Br. J. Dermatol. 2004; 151: 895-897.
14. Ahn C.S., Culp L., Huang W.W. et al.: Adherence in dermatology. J. Derma tol. Treat. 2017; 28(2): 94-103.
15. Bewley A., Page B.: Maximizing patient adherence for optimal outcomes in psoriasis. J. Eur. Acad. Dermatol. Venereol. 2011; 25(supl. 4): 9-14.
16. Fouere S., Adjadj L., Pawuin H.: How patients experience psoriasis: results from a European survey. J. Eur. Acad. Dermatol. Venereol 2005; 19(supl. 3): 2-6.
17. Zschocke I., Mrowietz U., Karakasili E, Reich K.: Non-adherence and measures to improve adherence in the topical treatment of psoriasis. J. Eur. Acad. Dermatol. Venereol. 2014; 28(supl. 2): 4-9.
18. Iversen L., Jakobsen H.B.: Patient preferences for topical psoriasis treatments are diverse and difficult to predict. Dermatol. Ther. 2016; 6: 273-285.
19. Reszke R., Szepietowski J.: Specjalistyczne podłoża dermatologiczne w terapii skojarzonej przewlekłych dermatoz. Forum Dermatol. 2016; 2: 97-101.